Understanding how smoking leads to lung fibrosis
Defining and targeting mechanisms of smoke-mediated fibrosis progression
This study is looking at how smoking affects the worsening of idiopathic pulmonary fibrosis (IPF) by examining changes in lung cells, with the hope of finding new ways to treat the disease and help patients better understand their condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10586073 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which tobacco smoking contributes to the progression of idiopathic pulmonary fibrosis (IPF), a severe lung disease. By analyzing gene profiles from lung fibroblasts affected by smoking, the study aims to identify specific molecular pathways and potential biomarkers associated with fibrosis. The researchers are particularly focused on the role of a protein called MARCKS and its interaction with the AXL receptor, which may provide insights into new therapeutic targets. Patients may benefit from a better understanding of their condition and potential new treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis, particularly those with a history of smoking.
Not a fit: Patients with lung fibrosis not related to smoking or those with other forms of lung disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients suffering from smoking-related lung fibrosis.
How similar studies have performed: Previous research has shown promising results in understanding the molecular mechanisms of lung diseases related to smoking, indicating that this approach may yield valuable insights.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Chen, Ching-Hsien — University of California at Davis
- Study coordinator: Chen, Ching-Hsien
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.